Barberry and Cardiometabolic Risk Factors in Individuals With Hypertriglyceridemia
Effect of Dried Barberry Consumption on Cardiometabolic Risk Factors in Individuals With Mild to Moderate Hypertriglyceridemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Zahra Kashani, Msc
- Phone Number: 09351442227
- Email: zahrakashani1401@gmail.com
Study Locations
-
-
Isfahan
-
Kāshān, Isfahan, Iran, Islamic Republic of
- Shahid Beheshty Unversity Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fasting serum triglycerides 150-499 mg/dL,
- Body mass index 25-40 kg/m2
- Age range 18-75 years
Exclusion Criteria:
- Regular use of drugs of the fibrate family, fish oil supplements or omega-3 supplements
- Regular consumption of flax seed or chia seed
- Treatment with glucocorticoids
- End-stage renal disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control
A diet with a reduced calorie intake
|
Diet with 500 kcal subtracted from the daily energy requirement
|
|
Experimental: Barberry
A diet with a reduced calorie intake, coupled with the consumption of barberry
|
Diet with 500 kcal subtracted from the daily energy requirement
Subjects will ingest 10 grams of powdered seedless barberry on a daily basis, in conjunction with the low-calorie diet.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma concentration of triglycerides
Time Frame: At baseline, the fourth week and the eighth week of study
|
The plasma triglyceride concentration 12 hours after the subjects had fasted
|
At baseline, the fourth week and the eighth week of study
|
|
Plasma concentration of high-density lipoprotein cholesterol (HDL-C)
Time Frame: At baseline, the fourth week and the eighth week of study
|
The plasma HDL-C concentration 12 hours after the subjects had fasted
|
At baseline, the fourth week and the eighth week of study
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight
Time Frame: At baseline, the fourth week and the eighth week of study
|
Body wight loss (kg)
|
At baseline, the fourth week and the eighth week of study
|
|
Plasma Cholesterol
Time Frame: At baseline, the fourth week and the eighth week of study
|
The plasma total cholesterol and LDL-C concentrations 12 hours after the subjects had fasted
|
At baseline, the fourth week and the eighth week of study
|
|
Plasma proprotein convertase subtilisin/kexin type 9 (PCSK9)
Time Frame: At baseline and the eighth week of study
|
The plasma PCSK9 concentration 12 hours after the subjects had fasted
|
At baseline and the eighth week of study
|
|
Plasma C-reactive protein
Time Frame: At baseline and the eighth week of study
|
The plasma CRP concentration
|
At baseline and the eighth week of study
|
|
Plasma Insulin
Time Frame: At baseline and the eighth week of study
|
The plasma insulin concentration 12 hours after the subjects had fasted
|
At baseline and the eighth week of study
|
|
Blood pressure
Time Frame: At baseline, the fourth week and the eighth week of study
|
Systolic and diastolic bliood pressure
|
At baseline, the fourth week and the eighth week of study
|
|
Urinary polyphenol
Time Frame: At baseline, the fourth week and the eighth week of study
|
Total polyphenol concentration in spot urine sample
|
At baseline, the fourth week and the eighth week of study
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Javad Nasrollahzadeh, Ph.D, Shahid Beheshti University of Medical Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 43008122
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.